Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment
- 1 November 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 3 (11), 1302-1315
- https://doi.org/10.1158/2159-8290.cd-13-0159
Abstract
Development of improved RNA interference–based strategies is of utmost clinical importance. Although siRNA-mediated silencing of EphA2, an ovarian cancer oncogene, results in reduction of tumor growth, we present evidence that additional inhibition of EphA2 by a microRNA (miRNA) further “boosts” its antitumor effects. We identified miR-520d-3p as a tumor suppressor upstream of EphA2, whose expression correlated with favorable outcomes in two independent patient cohorts comprising 647 patients. Restoration of miR-520d-3p prominently decreased EphA2 protein levels, and suppressed tumor growth and migration/invasion both in vitro and in vivo. Dual inhibition of EphA2 in vivo using 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) nanoliposomes loaded with miR-520d-3p and EphA2 siRNA showed synergistic antitumor efficiency and greater therapeutic efficacy than either monotherapy alone. This synergy is at least in part due to miR-520d-3p targeting EphB2, another Eph receptor. Our data emphasize the feasibility of combined miRNA–siRNA therapy, and will have broad implications for innovative gene silencing therapies for cancer and other diseases. Significance: This study addresses a new concept of RNA inhibition therapy by combining miRNA and siRNA in nanoliposomal particles to target oncogenic pathways altered in ovarian cancer. Combined targeting of the Eph pathway using EphA2-targeting siRNA and the tumor suppressor miR-520d-3p exhibits remarkable therapeutic synergy and enhanced tumor suppression in vitro and in vivo compared with either monotherapy alone. Cancer Discov; 3(11); 1302–15. ©2013 AACR. See related commentary by Kasinski and Slack, p. 1220 This article is highlighted in the In This Issue feature, p. 1207Keywords
All Related Versions
This publication has 35 references indexed in Scilit:
- RNA interference in the clinic: challenges and future directionsNature Reviews Cancer, 2010
- Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant gliomaTumor Biology, 2010
- Eph receptors and ephrins in cancer: bidirectional signalling and beyondNature Reviews Cancer, 2010
- EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian CarcinomaJNCI Journal of the National Cancer Institute, 2009
- RETRACTED ARTICLE: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinomaOncogene, 2004
- Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancerCancer Science, 2004
- MicroRNAs: Genomics, Biogenesis, Mechanism, and FunctionCell, 2004
- Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models.2003
- EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.2003
- Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth.2000